There were no synergistic effects of combined treatments.81 This is in accordance with a more recent study, which reported that SGLT2 users have a lower incidence of dementia compared with those on DPP-4 inhibitors.82 It is, therefore, likely that SGLT2 inhibitors may find some room in maintaining cognitive functions in people with T2DM.61 A double-blind, randomized placebo-controlled, parallel-group, 12-week study of the effects of dapagliflozin in people with AD is underway ( ClinicalTrials. Here, SLC5A2 is linked to Alzheimer disease.